Work

A phase Ib/IIa, open‐label, multiple ascending‐dose trial of domagrozumab in fukutin‐related protein limb‐girdle muscular dystrophy

Year: 2021

Type: article

Study design: Clinical Trial

Source: Muscle & Nerve

DOI: 10.1002/mus.27259

Authors: Doris G. Leung, Alex E. Bocchieri, Shivani Ahlawat, Michael A. Jacobs, Vishwa S. Parekh, Vladimir Braverman, Katherine Summerton, Jennifer Mansour, Nikia Stinson, Genila Bibat, Carl Morris, Shannon Marraffino, Kathryn R. Wagner

Institutions: Kennedy Krieger Institute, Johns Hopkins University, Johns Hopkins Medicine, Sidney Kimmel Comprehensive Cancer Center, Tulane University, Pfizer (United States)

Language: English

Topic: Muscle Physiology and Disorders

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

Funders: Pfizer, Limb Girdle Muscular Dystrophy 2i Research Fund, National Institute of Neurological Disorders and Stroke

Award: Magnetic resonance imaging and spectroscopy biomarkers for facioscapulohumeral muscular dystrophy

OpenAlex ID: W3158293831

FWCI: 0.785

Cites: 37

Cited by: 13

Related to: 10